Application of the peroxisome proliferator activated receptor gamma (PPARγ) Ligand rosiglitazone further increased the leptin concentrations in BAL [34], suggesting that treatment of obesity-related type II diabetes may result in higher leptin levels in the lung system. Here, PPARG is linked to type 2 diabetes mellitus.